Sign In
Buy MYGN
$4.31
+0.0300 (+0.701%)
At Close: Jun 02, 2026
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
11:07am, Tuesday, 28'th Apr 2026
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
09:15am, Thursday, 16'th Apr 2026
SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, in
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
09:15am, Tuesday, 14'th Apr 2026
SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Healt
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
09:15am, Thursday, 09'th Apr 2026
SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at
Myriad Genetics: SOTP Suggests The Company Is Undervalued
05:29pm, Tuesday, 31'st Mar 2026
Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. T
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 25'th Mar 2026
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term
10:45am, Thursday, 19'th Mar 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
10:51am, Wednesday, 18'th Mar 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth
10:10am, Tuesday, 24'th Feb 2026
Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth despite modest revenue decline. MYGN's core franchises—Prolaris and hereditary cance
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
08:45am, Tuesday, 24'th Feb 2026
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
10:54pm, Monday, 23'rd Feb 2026
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings
09:00pm, Monday, 23'rd Feb 2026
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates
08:26pm, Monday, 23'rd Feb 2026
Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million
